Lizenz: Creative Commons Namensnennung 3.0 de PDF - Veröffentlichte Version (4MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-553783
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.55378
Zusammenfassung
At present, targeting PD-1/PD-L1 axis for immune checkpoint inhibition has improved treatment of various tumor entities, including head and neck squamous cell carcinoma (HNSCC). However, one part of the patient cohort still shows little improvement or even hyperprogression. We established three radioresistant (RR) and three radiosensitive (RS) HNSCC cell lines. RR cells showed prolonged survival ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags